This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Biotech Sector Weekly Rewind

Stocks in this article: ENMD ISR HGSI DNDN AVNR ASTM EXEL

BOSTON ( TheStreet) -- Adam Feuerstein's take on the biotech week that was Nov. 19, 2010:

The week's best-performing stocks in the sector: Entremed (ENMD) (+41%), IsoRay (ISR - Get Report) (+33%), Exelixis (EXEL - Get Report) (+31%), Apricus BioSciences (APRI) (+29%) and China Shenghuo Pharmaceutical Holdings (KUN) (+26%)

FDA advisory panel votes 13-2 to recommend the approval of Human Genome Sciences' (HGSI) lupus drug Benlysta. Read the Human Genome FDA Panel Live Blog

Human Genome Hit by Benlysta Sales Worry

Takeda rumored to be eyeing a competing takeover offer for Genzyme (GENZ).

RXI Pharmaceuticals (RXII) says still on track to sign a major RNAi drug partnership before the end of the year.

> > Bull or Bear? Vote in Our Poll

Frontpoint Partners said to be shuttering health care hedge funds in wake of insider -trading allegations. (via New York Times)

The week's worst-performing stocks: Aastrom BioSciences (ASTM) (-43%), AP Pharma (APPA) (-28%), Neostem (NBX) (-26%), Vermillion (VRML) (-20%) and Alnylam Pharmaceuticals (ALNY) (-19%)

Medicare panel endorses on-label use of Dendreon's (DNDN) prostate cancer therapy Provenge.

Amgen (AMGN) rumored to be considering acquisition of Swiss biotech firm Actelion.

Roche cuts 4,800 jobs in a corporate restructuring that also axes the company's research efforts into RNAi drug development. (via Pharmalot, In the Pipeline)

European regulators accept approval application for Cell Therapeutics' (CTIC) lymphoma drug Pixuvri.

Exelixis (EXEL - Get Report): Interim phase II ovarian and prostate cancer data for XL184.

FDA advisory panel votes 8-7 with one abstention to recommend approval of MELA Sciences' (MELA) MELAFind skin cancer detection device. Read the MELA FDA Panel Live Blog

MELA Sciences Is Doomed

MELA Sciences: Not So Doomed

Aastrom BioSciences (ASTM) presents interim phase II data on limb ischemia drug.

Resverlogix (RVX.TO) presents phase II data on cholesterol drug.

FDA approves Amgen's (AMGN) Xgeva for prevention of bone fractures in cancer patients.

Somaxon Pharmaceuticals (SOMX) prices 8.8 million shares at $2.95 a share.

Pfizer (PFE) and Bristol-Myers Squibb (BMY) halt study of experimental blood thinner apixaban due to an increase in bleeding.

Results from late-stage study show Merck (MRK) drug boosts good cholesterol levels and cuts bad cholesterol without safety risks. (via Bloomberg)

Healthcare CEOs Make Big Dough (via WSJ Health Blog)

Bayer Cuts Jobs (via InVivo Blog)

Avanir Pharmaceuticals (AVNR) sells 20 million shares at $4.40 a share.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,387.21 -291.49 -1.65%
S&P 500 2,029.55 -27.54 -1.34%
NASDAQ 4,681.4970 -90.2660 -1.89%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs